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Background: Nitroglycerin is proposed as an agent to reduce tumour hypoxia by improving tumour per-
fusion. We investigated the potential of nitroglycerin as a radio-sensitizer in non-small cell lung cancer
(NSCLC) and the potential of functional imaging for patient selection.
Material and methods: Trial NCT01210378 is a single arm phase II trial, designed to detect 15% improve-
ment in 2-year overall survival (primary endpoint) in stage IB-IV NSCLC patients treated with radical
(chemo-) radiotherapy and a Transiderm-Nitro 5 patch during radiotherapy. Patients underwent dynamic
contrast-enhanced CTs (DCE-CT) and HX4 (hypoxia) PET/CTs before and after nitroglycerin. Secondary
endpoints were progression-free survival, toxicity and the prognostic value of tumour perfusion/hypoxia
at baseline and after nitroglycerin.
Results: The trial stopped after a futility analysis after 42 patients. At median follow-up of 41 months,
two-year and median OS were 58% (95% CI: 44–78%) and 38 months (95% CI: 22–54 months), respec-
tively. Nitroglycerin could not reduce tumour hypoxia. DCE-CT parameters did not correlate with OS,
whereas hypoxic tumours had a worse OS (p = 0.029). Changes in high-uptake fraction of HX4 and
tumour blood flow were negatively correlated (r = -0.650, p = 0.022). The heterogeneity in treatment
modalities and patient characteristics combined with a small sample size made further subgroup analysis
of survival results impossible. Toxicity related to nitroglyerin was limited to headache (17%) and
hypotension (2.4%).
Conclusion: Nitroglycerin did not improve OS of NSCLC patients treated with (chemo-)radiotherapy. A
general ability of nitroglycerin to reduce hypoxia was not shown.
 2019 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).f hypoxic
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Nitroglycerin is a commonly used vasodilator used in angina
pectoris or heart failure, which has been proposed as a potentially
valuable adjuvant drug in non-small cell lung cancer (NSCLC) treat-
ment. Yasuda et al. showed a significant survival benefit of adding
nitroglycerin to chemotherapy in stage IV non-small cell lung can-
cer in a randomized phase II study [1]. The authors hypothesized
this was due to increased tumour perfusion, also based on
decreased VEGF-levels found in surgically treated NSCLC tumours
in patients pre-treated with nitroglycerin. This result stimulated
others to initiate phase II trials investigating the addition of a nitric
oxide donor to different treatment regimens for NSCLC, all based
on the rationale of improved tumour perfusion resulting in
decreased tumour hypoxia [2–5].
We initiated a trial to test the effect of nitroglycerin on the OS of
NSCLC patients treated with radiotherapy. Because the proposed
beneficial effects of nitroglycerin on tumour perfusion and hypoxia
were never formally established in humans, patients were asked to
undergo a hypoxia PET scan and dynamic contrast enhanced CT
(DCE-CT) scan, both before and after treatment with nitroglycerin
[6]. We analysed the prognostic value of hypoxia HX4-PET and
DCE-CT imaging at baseline. Additionally, we assessed nitroglyc-
erin effects on hypoxia and tumour perfusion by comparing base-
line and nitroglycerin scans. The changes in imaging parameters
between the two time points were explored as a potential predic-
tive marker [7].2. Materials and methods
2.1. Clinical experiments
2.1.1. Study design
Patients with NSCLC stage Ib-IV referred to Maastro Clinic for
radical radiotherapy were eligible for inclusion in the prospective
trial NCT01210378 (see supplementary Table S1 for inclusion crite-
ria). The regional staging protocol includes 18FDG-PET-CT for all
patients and a brain MRI for patients with stage III-IV NSCLC. In
this trial, a nitroglycerin patch (Transiderm Nitro 5 mg, Novartis)
was applied on each day of irradiation, starting on day 1. These
patches contained 25 mg/10 cm2 and released nitroglycerin at
0.2 mg/h, identical to the patches used in the positive Yasuda trial.
Patients applied a patch at least 2 h prior to the first radiation ses-
sion of the day and removed the patch only after the last session of
the day in case of bi-daily treatments. Patients were asked to
undergo facultative scans to measure effects of nitroglycerin on
hypoxia and perfusion of the primary tumour. Hypoxia was evalu-
ated by the 2-nitroimidazole flortanidazole (3-[18F]fluoro-2-(4-((2-
nitro-1Himidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-propan-1-ol),
referred to as HX4-PET scans. Tumour perfusion was investigated
by dynamic contrast enhanced CT scanning (DCE-CT). DCE-CT
and HX4-PET scans were made at two time-points before start of
radiotherapy: once to measure baseline tumour perfusion and
hypoxia and a second time at least 48 h later, at a minimum of
1 h after application of a nitroglycerin patch (Fig. S1) [6]. The min-
imum inter-scan interval of 48 h was chosen to allow sufficient
time for kidney recuperation and wash-out of iodine contrast and
HX4 (HX4 biological T1/2 = 4.3 h, T1/2 18F = 110 min) to allow
accurate retesting [29].2.1.2. Follow-up and analysis
All patients were followed up according to standard follow-up
protocol including a CT-scan at 3 months post-treatment, repeated
yearly and whenever clinically indicated. Overall survival (OS),
loco-regional progression-free survival (LRPFS) and metastasis-free survival (MFS) were determined for all patients. OS was
defined as time between pathological diagnosis and death. LRPFS
and MFS were defined from the time of pathology until first pro-
gression on imaging, which was respectively a recurrence in pri-
mary tumour or regional lymph nodes, or distant metastases.
Kaplan Meier curves were constructed to analyse OS, LRPFS and
MFS for the HX4-PET and DCE-CT scans at baseline and after nitro-
glycerin application. Survival of patients with hypoxic tumours and
non-hypoxic tumours was analysed separately. For the DCE-CT
scans, the median BF and BV were used for patient stratification.
In addition, baseline median GTV and median FDG SUVmax and
SUVmean were tested for prognostic value.
The response to nitroglycerin was assessed by comparing base-
line and nitroglycerin HX4-PET and DCE-CT scans. Changes in
hypoxia and perfusion were marked as significant if they exceeded
the previously determined coefficient of repeatability (CoR). The
absolute CoR for HX4 was 0.30 for the TBR (tumour-to-blood ratio)
and 14.9% for the fraction of hypoxic volume: hypoxic fraction of
the GTV (FHV) with a threshold of TBR > 1.2. For perfusion the
CoR of Larici et al were adopted (BF 16.4%, BV 9.3%) [8,9].
2.2. Statistics
Primary endpoint was a 15% improvement in 2-year OS assum-
ing a 50% 2-year overall survival OS based on historical controls
treated at Maastro Clinic in 2010, with a one-sided alpha-value
of 0.10 and a power of 0.80. Reference survival assumed a distribu-
tion of 30% stage I, 10% stage II, 60% stage III and <5% stage IV
patients included in the trial population. This required inclusion
of 53 evaluable patients of whom 32 should be alive at 2 years after
diagnosis. Survival data were analysed using R (v3.3.2, Vienna,
Austria; survival package v2.38). For the imaging parameters, the
median and interquartile range (IQR) of the group of patients are
provided. Correlation coefficients were calculated using Spear-
man’s correlation coefficient. Survival statistics are presented as
the median with the 95% confidence interval (CI). Survival differ-
ences between groups were tested using a log-rank test. For all
analyses, the significance level was set at a two-tailed p-value
0.05.3. Results
We enrolled 47 of the initially planned 53 patients between
December 2011 and June 2016, 42 of which were evaluable: 3
withdrew consent, 2 were excluded because of wrongful inclusion
(re-irradiation of a recurrence after prior radical radiotherapy). In
July 2016 we performed an interim analysis after the NVALT-12
publication indicating a potentially negative effect of nitroglycerin
on survival [2]. At that time, median follow-up was 30 months and
18/42 patients had died. To reach 65% 2-year survival, all patients
still alive had to reach 2 years survival and at least 9 of 11 patients
still to be included would have to survive for 2 years. Institutional
Review Board and the Medical Ethical Trial Committee decided
that a benefit was highly unlikely and the trial was halted in July
2016.
3.1. Patient characteristics
Patient and treatment details are given in Table 1 and are
described in supplementary material and methods. Median age
was 60 years (range 36–82), 98% of patients had a WHO-PS 1.
Adenocarcinoma was the predominant histology (40%), while 26%
of patients had squamous cell carcinoma (see Table 1). Most
patients (64%) had stage III disease and 26% stage IV. Eight of 11
patients with stage IV disease were staged M1a (cervical nodes
Table 1
Patient and treatment characteristics.
Gender Male 24 (57%)
Female 18 (43%)
Age (mean, range; years) 60 (36–82)
GTV (median, range; cm3) Tumor 22 (0–477)
Nodes 15 (0–251)
Total 64 (6–497)
WHO-PS 0 9 (21%)
1 32 (76%)
2 1 (2%)
Charlson Comorbidity Index 0 22 (52%)
1 16 (38%)
2 3 (8%)
3 1 (2%)
Smoking Active 8 (19%)
Never 1 (2%)
Quit 31 (74%)
Unknown 2 (5%)
Treatment (thoracic) Radiotherapy 4 (10%)
Stereotactic radiotherapy 2 (5%)
Sequential chemoradiation 4 (10%)
Concurrent chemoradiation 32 (76%)
Radiotherapy schedules 60 Gy/2 Gy/QD 1 (2%)
60 Gy/7.5 Gy/3 fractions per
week
2 (5%)
INDAR:1.8 Gy/BID 8 (19%)
INDAR: 1.5 Gy/BID + 2 Gy/QD 31 (74%)
TNM (T) 1 1 (2%)
2 12 (29%)
3 10 (24%)
4 16 (57%)
X 3 (7%)
TNM (N) 0 6 (14%)
1 1 (2%)
2 18 (43%)
3 17 (41%)
TNM (M) 0 31 (74%)
1 11 (26%)
Site of metastases M1a
Cervical nodes 4 (10%)
Contralateral lung 4 (10%)
M1b
Adrenal 2 (5%)
Brain 1 (2%)
Stage I 2 (5%)
II 2 (5%)
III 27 (64%)
IV 11 (26%)
Pathology Adenocarcinoma 17 (40%)
Squamous cell carcinoma 11 (26%)
Large-cell carcinoma 10 (24%)
NSCLC NOS 4 (10%)
Table 2
Survival and progression data.
Nr of patients 42
Death Yes 21 (50%)
No 21 (50%)
Progressive disease Yes 24 (57%)
No 18 (43%)
Site of first progression Loco-regional 7 (16%)
Distant 13 (31%)
Loco-regional + distant 4 (10%)
Progression in PTV Yes 8 (19%)
- Tumour 2 (5%)
- Nodes 3 (7%)
- Tumour + nodes 3 (7%)
No 34 (81%)
Treatment at progression Radical intent 9 (21%)
- Surgery + chemo 1 (2%)
- Radiotherapy 7 (16%)
- Chemoradiation 1 (2%)
Palliative intent 9 (21%)
- Nivolumab 4 (10%)
- Gefitinib 1 (2%)
- Gemcitabin-Cisplatin 1 (2%)
- Pemetrexed 2 (5%)
- Radiotherapy 1 (2%)
Best supportive care 6 (14%)
Cause of death Progressive disease 14 (33%)
Infection 5 (12%)
Pneumonitis 1 (2%)
Terminal dementia 1 (2%)
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therapy due to neutropenic sepsis, but was included in the
intent-to-treat survival analyses. All other patients completed
radiotherapy. Four patients (10%) stopped nitroglycerin prior to
conclusion of radiotherapy, mostly after side-effects during con-
current chemoradiation (nausea in 2, pancytopenia in 1) and pul-
monary embolism in 1 patient.
3.2. Survival results
At a median follow-up of 41 months (range: 11–65 months),
21/42 patients had died. Two-year OS was 58% (95% CI: 44–78%),
median OS was 38 months (95% CI: 22–54 months) and PFS was
25 months (95% CI: 8–42 months). For stage III patients, the
2-year OS was 62% and the median OS 36 months (95% CI:
18.6–53.3 months). Twenty-four patients (57%) developed
progressive disease; mainly in the form of distant metastases.
The disease progressed inside the PTV in 8 patients (19%). Main
causes of death (Table 2) were disease progression (14 patients,
33%) and pulmonary infection (4 patients, 10%).3.3. Toxicity
All recorded adverse events are presented in Table S2. Hemato-
logic toxicity was most frequent: 34% of patients developed grade
3 neutropenia, while grade 3 thrombopenia were noted in 16%
and anemia in 19% of patients respectively. Grade 3 esophagitis
was seen in 4 patients (10%), all stage IV patients receiving concur-
rent chemoradiation.
Nitroglycerin related toxicity occurred in 7 patients (17%) men-
tioning headache and 1 patient with symptomatic hypotension
(2%).3.4. Imaging results
Acquisition and analysis of images are described in the supple-
mentary material and methods. Baseline and post-nitroglycerin
HX4-PET/CT scans were made in 32 and 25 patients respectively,
while baseline and post-nitroglycerin DCE-CTs were acquired in
22 and 13 patients respectively. The median interval between
baseline and second HX4 and DCE-CT scans was 4 and 5 days
respectively (range 2–7 days). No patients received chemo- or
radiotherapy during this interval. In Fig. 1, HX4-PET/CT scans and
BF and BV DCE-CT maps at baseline and after nitroglycerin in an
example patient are shown. Hypoxia was present in 25/31 primary
tumours (80%) while 16/25 nodal volumes (64%) were hypoxic.
Baseline HX4-TBR and HF showed a negative correlation with
blood flow (r = 0.451, p = 0.046 and r = 0.573, p = 0.008)
(Fig. S2).
For patients with baseline and post-nitroglycerin HX4-PET
imaging and a primary tumour (n = 24), the median TBR remained
unchanged after nitroglycerin: 1.4 (IQR: 1.2–1.8) vs 1.4 (IQR: 1.3–
1.8). Likewise, other hypoxia features did not show any significant
changes (Fig. 2). Numerically, more tumours and nodes were
hypoxic after nitroglycerin: 19/24 tumours (79%) vs 21/24 tumours
(87.5%) and 9/18 nodal volumes (50%) vs 10/18 nodal volumes
(55%). A reduction in hypoxia exceeding the CoR was found in only
1 GTVp based on the TBR threshold and in 2 GTVp based on the
HX4-HF threshold. The HX4-TBR increased by more than CoR in
Fig. 1. HX4-PET/CT scan, blood flow (BF) and blood volume (BV) DCE-CT maps of a representative patient, at baseline and after applying a nitroglycerin patch. In this
patient, the hypoxic volume decreased from 70 cm3 to 64 cm3, while the average BF increased from 37 ml/100 ml/min to 54 ml/100 ml/min, and the average BV increased
from 5.8 ml/100 ml to 8.6 ml/100 ml.
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(4%). The effect of nitroglycerin on HX4-TBR in GTVp correlated
with the effect in GTVn in the same patients (r = 0.701, p = 0.002).
For the 13 patients with baseline and post-nitroglycerin DCE-CT
scans, there was no difference between the median BF before or
after nitroglycerin: 63.6 (IQR: 52.0–81.2) vs 53.8 (IQR: 44.8–78.4)
ml/100 ml/min (p = 0.087) or the median BV: 7.5 (IQR: 5.8–9.4)
at baseline vs 7.2 (IQR: 6.9–8.6) ml/100 ml after nitroglycerin
treatment (p = 0.972). A significant increase in BF was present in
1 tumour and a decrease was seen in 4. Blood volume increased
significantly in 4 tumours and decreased in another 4 [8]. In the
12 patients who received the full set of scans we found a negative
correlation between the change in HF with the change in BF
(r = 0.650, p = 0.022), but not between other parameters.
The Kaplan Meier curves assessing the prognostic value of base-
line imaging are presented in Fig. 3 for hypoxia PET imaging and in
Fig. S3 for DCE-CT imaging. A significant difference in OS (p = 0.029)
was observed between patients with hypoxic tumours (2-year OS
47%; 95% CI: 31–72%) and non-hypoxic tumours (2-year OS 100%;
95% CI: 100–100%). Patients with hypoxic tumours also exhibited
a worse MFS (p = 0.045) while LRPFS was not significantly different
between baseline hypoxic and non-hypoxic tumours (p = 0.23)(Fig. 3). None of the other factors examined (total GTV, FDG-
SUVmax or FDG-) were prognostic in this patient cohort.
Kaplan Meier curves based on the scans with nitroglycerin
patch are shown in Fig. S4 for hypoxia PET imaging and in Fig. S5
for the DCE-CT imaging features. For the 24 patients with a nitro-
glycerin scan and primary tumour, no significant differences were
found between patients with post-nitroglycerin hypoxic and non-
hypoxic tumours for OS (p = 0.14), MFS (p = 0.19) or LRFS
(p = 0.99). In 13 patients with a nitroglycerin DCE-CT scan, no sur-
vival differences were found for different levels of BF or BV. Since
too few patients had a hypoxia response, a separate survival anal-
ysis was irrelevant.4. Discussion
In this trial we could not demonstrate a significant survival ben-
efit from the addition of nitroglycerin to radiotherapy for NSCLC
patients. After the negative results of several other simultaneous
trials, ours also ended prematurely because of the inability to reach
the primary endpoint. Overall, the survival, loco-regional relapse
and distant metastases rates are in the range of those, previously
Fig. 2. Boxplots of HX4-PET and DCE-CT imaging characteristics for the primary tumour for patients with both a baseline and nitroglycerin scan. For the HX4-PET, the mean
uptake (SUVmean), tumour-to-background ratio (TBR), hypoxic volume (HV), and fraction of HV (FHV) are given. For the DCE-CT images, the average blood flow (BF) and blood
volume (BV) are shown. The observations of patients with two scans are connected with a line. The HX4-PET imaging features are shown for 24 patients; the DCE-CT features
were available for 13 patients.
Fig. 3. Prognostic value of baseline HX4-PET imaging of the primary tumour, with from left to right the overall survival (OS), metastasis-free survival (MFS) and loco-regional
progression free survival (LRPFS). In total 32 patients received a baseline HX4-PET/CT. The 31 patients with a primary tumour are displayed in the graph.
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with concurrent individualized accelerated radiotherapy (INDAR)
and the ESPATU-trial on which the INDAR schedule was based
[10,11]. Our trial was designed in 2010, and a 2-year overall sur-
vival of 65% was thought to represent a clinically relevant improve-
ment relative to standard treatment to follow through with a phase
III trial. In more recent trials where treatment at relapse also incor-
porates targeted therapy, 2-year survival rates of 60% and higher for
stage III patients are regularly reported [11,12]. This aggressive
approach of relapsing patients can also be seen in our trial, where
2/3 of patients with progressive disease received second line treat-
ment, half of which had radical intent. Therefore, at interim analysis
the trial staff decided that even a 65% 2-year survival would not
represent an improvement over standard care to justify phase III
testing.
Combining nitroglycerin with standard treatment, toxicity was
mild. The most frequent toxicity was neutropenia. Our rate of 39%
in patients receiving chemotherapy is in the range of the 30–60%
rates reported in other trials using cisplatin-doublet chemotherapy
with nitroglycerin. Headache was only reported by 17% of patients
and did not exceed grade 2. This is in line with the results of other
trials using a 25 mg patch. In the NVALT-12 trial the rate of grade
3 headache was 12.1% and 20% of patients stopped nitroglycerin
because of headache. In that trial however, a patch containing
75 mg of nitroglycerin was used [1,2,5].
FDG-PET, DCE-CT imaging parameters and total GTV did not cor-
relate with survival in this cohort, but patients with baseline
hypoxic primary tumours had a worse prognosis than patients with
normoxic tumours. Other nitro-imidazole based PET tracers, FMISO,
FAZA and FETNIM [13–16], already showed to be prognostic in
NSCLC, but this is the first prospective trial to find this correlation
for HX4. Whether this is independent of other factors (such as
GTV or pathology) should be investigated in larger cohorts, since
the limited number of patients with baseline hypoxia precludes
extensive multivariate analysis. The difference in survival rate
between patients with hypoxic and non-hypoxic primary tumours
is related to a difference in metastasis free survival, rather than
loco-regional control rate. Allmetastases developed in patientswith
a hypoxic primary tumour, which correlates with the observation
that hypoxia selects cells with a more aggressive and metastasis-
prone phenotype and enables metastatic spread [17,18].
The main rationale underlying all trials investigating nitroglyc-
erin as an adjunct to standard treatment modalities for NSCLC is
enhanced tumour perfusion attributed to the vasodilating proper-
ties of nitroglycerin [1,2,4,5]. This was also proposed by Yasuda to
explain the lower VEGF levels observed in NSCLC tumours in oper-
ated patients pre-treated with nitroglycerin and in the blood of
patients treated with nitroglycerin prior to chemotherapy [19].
Although enhanced tumour perfusion was previously shown, our
results do not support a general tumour perfusion increase in
human NSCLC: most tumours showed no significant changes.
Moreover, one in six volumes exhibited a significant increase in
HX4 uptake after treatment with nitroglycerin and a significant
decrease in BF and BV was found in almost a third of tumours. This
observation correlates with warnings that NO should be consid-
ered a ‘double-edged sword’ in cancer treatment [20]. As NO is
not a targeted agent focusing its actions solely on the tumour vas-
culature, its systemic effect on peripheral vessels could cause a
steal phenomenon in adequately perfused tumours, shifting blood
away from the tumour to the systemic vasculature [21,22]. Blood
pressure measurements at the time of scanning could have offered
more information, but were not obtained. According to several
investigators an alternative mechanism of action of nitroglycerin
could be NO-mediated inhibition of mitochondrial oxygen con-
sumption [23–26]. In a separate in vitro experiment (see supple-
ments) we also didn’t observe a reduced oxygen consumptionrate upon exposure to human plasma levels of nitroglycerin or
even 100,000 fold higher (Fig. S6), which is in contrast with earlier
reports [27]. This can be explained by our use of stabilisation agent
free nitroglycerin. Often saccharides are used to stabilize nitroglyc-
erin [28], which can upregulate the glucose metabolism and sur-
pass mitochondrial respiration.
Our observations present an argument against the general appli-
cation of nitroglycerin in unselected patients and highlight the need
patient stratification and selection. We hypothesized that
nitroglycerin-induced differences in hypoxia levels, as measured
on HX4-PET/CT scans, could aid selection of patients for nitroglyc-
erin treatment, but due to the limited number of patients and the
heterogeneous patient group, we could not confirm this hypothesis.
There are caveats to this study. We used a TBR of 1.2 to distin-
guish between hypoxic and non-hypoxic tumours. However, a for-
mally established threshold is missing and several different
thresholds have been proposed for nitro-imidazole based PET trac-
ers [29]. The threshold used to divide the patients in nitroglycerin
responders and non-responders based on their hypoxia status is
arbitrary andmay have been too strict for this study, limiting detec-
tion of responders. Also, the HX4-PET scans used by Zegers et al. to
calculate the coefficients of repeatabilitywere acquired shortly after
injection of the PET tracer [9]. These scans will have less optimal
contrast to noise ratios compared to the scans used in this study
[29]. The expected lower noise levels in this study will arguably
yield a higher reproducibility, thus smaller changes in hypoxia
levels could be ascribed to nitroglycerin administration. The averag-
ing of all imaging features over the whole tumour is also a limiting
factor: tumour vasculature is highly irregular anddifferences in per-
fusion and hypoxia levels can be local andheterogeneous [30,31]. By
averaging the imaging features over a large region, regional nitro-
glycerin effects might be left unappreciated. Possibly not the aver-
age blood flow, but the distribution and redistribution of the blood
flow might be more relevant for reducing hypoxia and improving
chemotherapy accessibility [31]. Sub-regional tumour analysis
could yield valuable information on local differences, however,
our small patient group limits this more advanced analysis [32,33].
The studied patient group is small and more heterogeneous
than expected beforehand: NSCLC patients (stage IB-IV) were
included, receiving a wide range of (combined) treatments, making
interpretation of survival for subgroups difficult. While multiple
factors thus could have influenced survival, further subgroup anal-
ysis or multivariate analysis is restricted due to the limited number
of patients. Randomisation with a placebo study group could have
limited these influences, but we chose the single arm format to
encourage patient participation in view of several simultaneously
running, but slowly recruiting randomized phase III trials (eg
NVALT-11 and PET-BOOST).
In conclusion, this study adds to the list of trials that could not
demonstrate a benefit of adding nitroglycerin as a sensitizing agent
to classical treatment of NSCLC patients. We did show for the first
time the negative prognostic significance of increased uptake of
the hypoxia tracer HX4. In an exploratory analysis we demon-
strated that nitroglycerin can exert both increases and decreases
in hypoxia, varying between individuals and correlated with both
negative or positive variations induced in tumour BF. Selection of
patients who could benefit from treatment with nitroglycerin
based on imaging parameters wasn’t possible, but in any case these
results don’t support the hypothesis that nitroglycerin can serve as
a general hypoxia sensitizing agent in unselected patients.
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